Home » Newsletters » BioWorld Science

BioWorld Science

June 4, 2020

View Archived Issues

Ovarian organoids implicate oviducts

iPSC microtissue gives clues to heart disease

Estrogen and dopamine

Identification of a JAK inhibitor selectively targeting GI tissues for inflammatory bowel disease

A new ASK1 inhibitor presenting brain penetration

FDA accepts IND for phase I/II trial of Treadwell's HPK1 inhibitor CFI-402411

Brukinsa receives approval in China for patients with CLL/SLL and MCL

First patient data presented for PF-06804103 antibody-drug conjugate

Rgenix presents monotherapy dose-escalation data from phase I study of RGX-202

Phase II data reported from TreeTopp study of varlitinib plus capecitabine in BTC

FDA gives FSD Pharma permission to submit IND for phase IIa trial of FSD-201 for COVID-19

Ube Industries discloses cyclin-dependent kinase 7 inhibitors

Shanghai Ennova Biopharmaceutical patents neurotrophic tyrosine kinase receptor inhibitors

New MAP4K1 inhibitors discovered at Pfizer

New monobactam compounds presented by Nanjing Sanhome Pharmaceutical

Idorsia Pharmaceuticals identifies new Ox1-R and Ox2-R antagonists

Data questions arise for two major COVID-19 studies

Kezar reports updated phase Ib findings on KZR-616 in SLE

Maxinovel studies MAX-10181 for advanced solid tumors in first-in-human trial

Kadmon begins first-in-human study of KD-033 in metastatic or locally advanced solid tumors

European approval for Braftovi with cetuximab for BRAF V600E-mutant metastatic colorectal cancer

ImmuneOncia begins first-in-human study of IMC-002 for advanced solid tumors and lymphomas

Phase II dose defined in trial of CBL-0137 in patients with solid tumors

Pilot study evaluates DNAJB1-PRKACA peptide vaccine for fibrolamellar hepatocellular carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...